BioWorld

Jan. 3, 2007

UK Firm Spirogen Focuses On DNA-Targeted Therapies

Nearly three years after moving its first agent into Phase I trials, Spirogen Ltd. is starting off 2007 with similar plans for a second compound. (BioWorld Today) Read More

Biomira Launches Clinical Trials Of Cancer-Fighting Therapies

New Studies Show How Host, Gut Guests And Weight Relate

New Breast Cancer Gene Moves Focus To Role Of DNA Repair

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 3, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

EASL 2026: Emerging liver disease targets to watch

BioWorld

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...